Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00021359 · ClinicalTrials.gov registry record · Phase 2
Isotretinoin Plus Dexamethasone in Treating Patients With Multiple Myeloma
A Phase 2 study, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT00021359 is a Phase 2 study that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 17 participants.
The verdict
NCT00021359, a Phase 2 study, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with dexamethasone may be an effective treatment for multiple myeloma. PURPOSE: Phase II trial to study the effectiveness of combining isotretinoin and dexamethasone in treating patients who have multiple myeloma.
Interventions
- DRUG dexamethasone
- DRUG isotretinoin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 1999-08 |
| Est. Completion | 2005-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00021359
The ClinicalTrials.gov registry entry for NCT00021359 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which dexamethasone is the first listed.
NCT00021359 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00021359 about?
NCT00021359 is a clinical study titled "Isotretinoin Plus Dexamethasone in Treating Patients With Multiple Myeloma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with dexamethasone may be an effective treatment for multiple myeloma. PURPOSE: Phase II trial to study the effectiveness of combining isotretinoin and dex...
What is the current status of trial NCT00021359?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 1999-08. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00021359?
The interventions under investigation include: dexamethasone (DRUG), isotretinoin (DRUG).
Who is sponsoring clinical trial NCT00021359?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.